



## IN THE CLAIMS

This claim listing replaces all the previous claim listings.

1. (Canceled)
2. (Currently amended) A cyclic peptide structure with a general formula of CCRGDVLD<sub>n</sub>X<sub>m</sub>Y-CCR/HGDV/LLD/E<sub>n</sub>X<sub>m</sub>Y, in which formula X is any hydrophobic amino acid and Y is any hydrophilic amino acid, and the index n is 1, 2 or 3 and index m is 1, 2 or 3, said peptide structure having a capability to regulate apoptotic cell death.
3. (Previously presented) The peptide structure of Claim 2 further having 0, 1, 2 or 3 flanking cysteine residues at the N-terminus and 0, 1, 2, or 3 flanking cysteine residues at the C-terminus of the peptide.
4. (Withdrawn) The peptide structure of Claim 3, wherein the peptide structure is further selected from a group consisting of linear and cyclic.
5. (Previously presented) The peptide structure according to Claim 2, wherein the peptide further consists of sequences RGD and DXXD, and wherein X means any hydrophobic amino acid residue and R, G and D mean Arg, Gly and Asp, respectively.

6. (Previously presented) The peptide structure according to Claim 5, wherein D of sequence RGD is common with the sequence DXXD.
7. (Previously presented) The peptide structure according to Claim 2, wherein X in the general formula means V, L or W, Xm may contain any combination of V, L and W, and Y means D, E, or G.
8. (Currently amended) The peptide structure according to claim 3, wherein the peptide structure is further defined as C\*C\*RGDVLDC\*  
~~C\*C\*R/HGDV/LLD/EC\*~~, and the asterisk residues denote to places of possible disulfide bonds.
9. (Canceled)
10. (Previously presented) A method for suppressing apoptotic regulatory pathways in human and animal cells by treating the cells with peptide structures according to claim 2 for an appropriate period of time.
11. (Currently amended, Withdrawn) A method to increase preservation of organs or cells within their transplantation by using ~~use of~~ the peptide structures of Claim 2. ~~for increasing preservation of organs or cells within their transplantation.~~


12. (Currently amended, Withdrawn) A method to prevent autoimmune disorders and an immunodeficiency syndrome induced by a viral infection by ~~A- use of the peptide structures of Claim 2. for prevention of autoimmune disorders and an immunodeficiency syndrome induced by a viral infection.~~
13. (Currently amended, Withdrawn) A method to lower cytotoxic effects after chemo- or radiotherapy by use of ~~using~~ the peptide structures of Claim 2 ~~for lowering cytotoxic effects after chemo- or radiotherapy.~~
14. (Currently amended) A method to inhibit cell apoptosis by using ~~use of~~ the peptide structures of Claim 2 ~~for inhibition neuronal cell apoptosis, non-specific drug-induced apoptosis, or oxidative stress-mediated apoptosis.~~
15. (Previously presented) The method according to claim 10, wherein the cells are cultured for scientific or technical purposes.
16. (Currently amended) The molecular structure according to Claim 2, wherein the structure has an ability to bind into an antibody prepared against the molecular recognition site of a FGab-fragment or said anti-idiotypic antibody.
17. (Currently amended) The peptide structure of Claim 2 [4], wherein the peptide is polymerized.

18. (Previously presented) The peptide structure of Claim 17, wherein the peptide structure is cyclic dimer.


19. (Previously presented) The peptide structure of Claim 18, wherein the structure is:



20 (Withdrawn) The peptide structure of claim 18 wherein the structure is:



21(Withdrawn) The peptide structure of claim 18, wherein the structure is:



22. (New) The method of claim 14, wherein the apoptosis is selected from the group consisting of neuronal cell apoptosis, non-specific drug-induced apoptosis, and oxidative stress –mediated apoptosis.